Cargando…
Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence
In this critical review, we explore the study design, strengths, and limitations of landmark trial “Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence”. This trial was the first to directly compare two key treatment options for urge urinary incontinence – anticholinergic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210496/ https://www.ncbi.nlm.nih.gov/pubmed/37226116 http://dx.doi.org/10.1186/s12894-023-01273-y |
_version_ | 1785047078361104384 |
---|---|
author | Shugg, Nathan O’Callaghan, Michael E. |
author_facet | Shugg, Nathan O’Callaghan, Michael E. |
author_sort | Shugg, Nathan |
collection | PubMed |
description | In this critical review, we explore the study design, strengths, and limitations of landmark trial “Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence”. This trial was the first to directly compare two key treatment options for urge urinary incontinence – anticholinergic medication and intravesical botox, and still influences clinical guidelines a decade after publication. This non-inferiority, double-blinded, multi-centre randomised controlled trial administered Solifenacin or intra-detrusor botox to women, measuring outcomes six months post-treatment. Non-inferiority of the treatments was established, though Botox had a higher rate of retention and infection, with side effect profile rising as the key discriminator in selecting first-line therapy. |
format | Online Article Text |
id | pubmed-10210496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102104962023-05-26 Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence Shugg, Nathan O’Callaghan, Michael E. BMC Urol Review In this critical review, we explore the study design, strengths, and limitations of landmark trial “Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence”. This trial was the first to directly compare two key treatment options for urge urinary incontinence – anticholinergic medication and intravesical botox, and still influences clinical guidelines a decade after publication. This non-inferiority, double-blinded, multi-centre randomised controlled trial administered Solifenacin or intra-detrusor botox to women, measuring outcomes six months post-treatment. Non-inferiority of the treatments was established, though Botox had a higher rate of retention and infection, with side effect profile rising as the key discriminator in selecting first-line therapy. BioMed Central 2023-05-24 /pmc/articles/PMC10210496/ /pubmed/37226116 http://dx.doi.org/10.1186/s12894-023-01273-y Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Shugg, Nathan O’Callaghan, Michael E. Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title | Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title_full | Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title_fullStr | Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title_full_unstemmed | Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title_short | Seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
title_sort | seminal papers in urology: anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210496/ https://www.ncbi.nlm.nih.gov/pubmed/37226116 http://dx.doi.org/10.1186/s12894-023-01273-y |
work_keys_str_mv | AT shuggnathan seminalpapersinurologyanticholinergictherapyvsonabotulinumtoxinaforurgencyurinaryincontinence AT ocallaghanmichaele seminalpapersinurologyanticholinergictherapyvsonabotulinumtoxinaforurgencyurinaryincontinence |